Clinical trials: SLE Nephritis
Lupus Erythematosus, Lupus Nephritis
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
- Trial name
- EQUALISE (NCT04128579)
- Testing
- Itolizumab [Bmab 600]
- Where
- 25 sites in United States, India and 1 more
- Volunteers
- 52 people
- Sponsor
- Biocon Limited
S100A8, Serum
S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis
This study aims to evaluate both serum and urine S100A8 as potential biomarkers for Lupus nephritis (LN)
- Conditions
- S100A8, Serum, Urine, Biomarker
- Trial name
- NCT06872138
- Where
- Egypt
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Theodor Bilharz Research Institute
Lupus Erythematosus, Systemic, Lupus Nephritis
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active…
- Trial name
- NCT06581198
- Testing
- rapcabtagene autoleucel
- Where
- 107 sites in United States, Argentina and 24 more
- Volunteers
- 179 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Lupus Nephritis
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
- Trial name
- NCT06544330
- Testing
- SYNCAR-001, STK-009
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Synthekine
Lupus Nephritis
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis
The objective of this study is to evaluate the efficacy and safety of Tacrolimus capsules for induction remission in patients with lupus nephritis, and compare the efficacy and safety with Cyclophosphamide injections.
- Trial name
- NCT02457221
- Testing
- Tacrolimus capsules, Cyclophosphamide injections, Prednisone
- Where
- 35 sites in China
- Volunteers
- 314 people
- Sponsor
- Astellas Pharma China, Inc.
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
Lupus Nephritis
Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients
Systemic Lupus Erthymatosous (SLE) is achronic inflammatory multi system auto immue disease characterized by pathogenic auto anti bodies production against nuclear structures (Bolouri et al.,2022), SLE affecting mainly woemn of…
- Trial name
- NCT06631404
- Testing
- renal doppler
- Where
- Egypt
- Volunteers
- 55 people
- Sponsor
- Sohag University
Lupus Nephritis (LN), SLE - Systemic Lupus Erythematosus
The Relation of Albumin/Globulin Ratio and Platelet/Albumin Ratio to Lupus Nephritis
Albumin/globulin ratio and platelet/albumin ratio as a predictive non-invasive biomarker for lupus nephritis (LN) presence and severity
- Conditions
- Lupus Nephritis (LN), SLE - Systemic Lupus Erythematosus, Biomarkers
- Trial name
- NCT07130448
- Volunteers
- 120 people
- Sponsor
- Assiut University
Lupus Nephritis
Rituximab and Belimumab for Lupus Nephritis
In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab…
- Trial name
- CALIBRATE (NCT02260934)
- Testing
- Rituximab, Cyclophosphamide, Prednisone
- Where
- 15 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07305116
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Proteinuria, Kidney Injury
Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease
This study will evaluate in patients with kidney disease, the role that certain inflammatory and immune mediators play in promoting kidney damage.
- Conditions
- Proteinuria, Kidney Injury, Chronic Kidney Disease
- Trial name
- NCT01156428
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- The Rogosin Institute
Lupus Nephritis
Etanercept for the Treatment of Lupus Nephritis
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease in which the body's immune system attacks its own normal tissues.
- Trial name
- NCT00447265
- Testing
- Etanercept, Lupus Treatment- Standard of Care
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis, Systemic Lupus Erythematosus
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory…
- Conditions
- Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III
- Trial name
- RECLAIM-LN (NCT07570862)
- Testing
- FT819
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Fate Therapeutics
Lupus Nephritis
A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis
This study will compare the efficacy of CellCept [0.5-2 grams per day (g/day) orally (p.o.)] and cyclophosphamide [0.5-1 grams per square meter (g/m2) quarterly] as maintenance treatment for patients with lupus nephritis.
- Trial name
- NCT02081183
- Testing
- Mycophenolate mofetil (MMF), Cyclophosphamide, Maintenance Phase, Cyclophosphamide, Induction Phase
- Where
- 2 sites in Venezuela
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Lupus or SLE, Nephritis
Use of Baricitenib to Maintain of Remission
Baricitinib a selective Janus kinase (JAK) inhibitors 1\&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the…
- Trial name
- NCT05686746
- Testing
- Baricitinib 4 MG, Baricitinib 2 MG, MMF
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Proliferative Nephritis, Chloroquine Retinopathy
Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine
Evaluation the efficacy of chloroquine and hydroxychloroquine in the treatment of proliferative lupus nephritis class III and IV in children and adolescents and evaluate the side effects of both drugs .
- Trial name
- NCT03687905
- Testing
- Chloroquine, Hydroxychloroquine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Systemic Lupus Erythematosus
Prediction of Outcome of Lupus Nephritis
The purpose of this study is to clarify the mechanisms involved in the formation and glomerular deposition of immune complexes in lupus nephritis.
- Trial name
- NCT02403115
- Testing
- Serum collection
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Istituto Giannina Gaslini
Lupus Nephritis, Lupus Erythematosus, Systemic
Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis
The investigators study the efficacy and safety of tacrolimus in the treatment of membranous nephritis secondary to systemic lupus erythematosus.
- Trial name
- NCT00125307
- Testing
- tacrolimus
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Lupus Nephritis
A Study of ANX009 in Adult Participants With Lupus Nephritis
The main purpose of this study is to determine the safety and tolerability of repeat doses of ANX009 in participants with lupus nephritis (LN).
- Trial name
- NCT05780515
- Testing
- ANX009
- Where
- 7 sites in Philippines, Taiwan
- Volunteers
- 7 people
- Sponsor
- Annexon, Inc.
Glomerulonephritis, Lupus Nephritis
Cyclophosphamide and Fludarabine to Treat Lupus Nephritis
This study will test the safety and effectiveness of combination therapy with cyclophosphamide (Cytoxan) and fludarabine in treating lupus nephritis (kidney inflammation).
- Conditions
- Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus
- Trial name
- NCT00001676
- Testing
- SQ Fludarabine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)